AzTrials
AzTrials

Athletic PerformanceNAP-CAF-RECNCT07652424

Effects of Afternoon Napping, Caffeine, and Standardised Active Recovery on Evening Athletic Performance

A study testing Afternoon Nap, Caffeine and Standardised Active Recovery and Nutritional Protocol in people with Athletic Performance and Sports Performance, run by The Higher Institute of Sport and Physical Education of Sfax at 1 site in Tunisia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study evaluated whether afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol could influence evening physical and cognitive performance in healthy university athletes. Read more about this study

Who is it for?
Ages 18 to 25 yearsHealthy volunteers can take part
What is being tested?
Afternoon Nap, Caffeine and Standardised Active Recovery and Nutritional Protocol
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteTunisia
Study dates
2 Jan 2025to 31 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 25 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy university athletes aged 18-25 years.
  • Regular engagement in structured training, defined as at least 10 training sessions per week of approximately 2 h each, across team sports, judo, athletics, tennis, or swimming.
  • Non-habitual napping, defined as fewer than one nap per week.
  • Low habitual caffeine intake, defined as <80 mg/day, assessed using a 7-day dietary recall.
  • Non-smoker and free from regular medication or recreational drug use.
  • No musculoskeletal injury during the preceding month.
Show all 9Show fewer
  • Good self-reported sleep quality, defined as a Pittsburgh Sleep Quality Index score <5.
  • Definite morning chronotype (MEQ score 59-86) or definite evening chronotype (MEQ score 16-41).
  • For female participants: self-reported regular menstrual cycles (26-32 days), no hormonal contraceptive use, and no self-reported history of menstrual disorders.

Who cannot join

  • Intermediate chronotype (MEQ score 42-58).
  • Habitual napping (≥1 nap per week).
  • Habitual caffeine intake ≥80 mg/day.
  • Smoking, regular medication use, or recreational drug use.
  • Musculoskeletal injury during the preceding month.
  • Pittsburgh Sleep Quality Index score ≥5.
Show all 9Show fewer
  • Self-reported irregular menstrual cycles, hormonal contraceptive use, or history of menstrual disorders in female participants.
  • Self-reported sleep disorder.
  • Inability or unwillingness to complete all five experimental conditions.

Trial locations and contacts

1 site in 1 country.

Tunisia1 site
  • Higher Institute of Sport and Physical Education of Sfax (ISSEP Sfax)

    Sfax, 3000

Other trials in Tunisia

About this study

Official title: Effects of Afternoon Napping, Caffeine, and a Standardised Active Recovery Protocol on Evening Athletic Performance According to Sex and Chronotype: A Randomised Crossover Trial

This study evaluated whether afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol could influence evening physical and cognitive performance in healthy university athletes.

Participants completed five experimental conditions in a randomised crossover design: placebo without napping, napping with placebo, caffeine without napping, napping combined with caffeine, and napping combined with caffeine plus a standardised active recovery and nutritional protocol. The nap opportunity lasted 90 minutes and caffeine was administered at 5 mg/kg body mass.

The main outcome was repeated agility performance. Additional outcomes included sprint performance, jumping performance, reaction time, subjective sleepiness, sleep characteristics during the nap opportunity, and selected physiological measures. The study also explored whether responses differed according to sex and chronotype.

Read the detailed description

This randomised, placebo-controlled crossover study examined the isolated and combined effects of afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol on evening athletic performance.

Participants completed five experimental conditions in a counterbalanced Latin-square order, with at least 72 h between sessions:

  1. PLA: placebo capsule at 18:00, without a nap opportunity.
  2. NAP: 90-min nap opportunity from 13:00 to 14:30 plus placebo capsule at 18:00.
  3. CAF: caffeine ingestion at 18:00 (5 mg/kg body mass) without a nap opportunity.
  4. NAP+CAF: 90-min nap opportunity plus caffeine ingestion at 18:00.
  5. NAP+CAF+REC: 90-min nap opportunity plus caffeine ingestion at 18:00 and a standardised active recovery and nutritional protocol from 18:45 to 19:00.

The active recovery and nutritional protocol included a standardised lower-limb dynamic stretching routine followed by a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate. The protocol was identical for all participants allocated to this condition.

Participants were stratified by sex and chronotype before condition allocation. Capsule allocation was double-blinded: participants, outcome assessors, and the testing team were unaware of whether caffeine or placebo had been administered. Blinding of nap and active recovery components was not possible because of the nature of these interventions.

The primary outcome was total time during the Repeated Modified Agility Test. Secondary performance outcomes included 20-m sprint time, countermovement jump height, squat jump height, simple reaction time, choice reaction time, and subjective sleepiness. Nap sleep characteristics were assessed using portable electroencephalographic monitoring. Physiological measures included heart-rate variability, salivary cortisol, plasma brain-derived neurotrophic factor, and blood lactate.

All sessions were conducted under standardised sleep, dietary, and activity-control procedures. The study explored whether intervention responses differed by sex and chronotype.

Being tested
Afternoon Nap, Caffeine, Standardised Active Recovery and Nutritional Protocol, Placebo
Keywords
Napping, Caffeine, Recovery Protocol, Chronotype, Sex Differences, Evening Performance, Crossover Trial, Randomised Controlled Trial, Brain-Derived Neurotrophic Factor, Heart Rate Variability, Reaction Time, Agility, Jump Performance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Afternoon NapBehavioural

    A 90-min afternoon nap opportunity from 13:00 to 14:30 in a quiet, dimly lit, temperature-controlled room. Sleep was monitored using a portable EEG headband. Participants were provided with earplugs and eye masks, and nap sleep characteristics, including sleep stages, were recorded.

  • CaffeineDietary supplement

    Anhydrous caffeine (5 mg/kg body mass) was administered orally in an opaque capsule at 18:00. Placebo capsules contained microcrystalline cellulose and were matched for appearance, mass, colour, and odour. Capsule allocation was blinded to participants and outcome assessors.

  • Standardised Active Recovery and Nutritional ProtocolCombination product

    A 15-min standardised active recovery and nutritional protocol performed from 18:45 to 19:00. It included lower-limb dynamic stretching exercises (forward/backward and lateral leg swings, walking lunges, high knees, and butt kicks; 10 repetitions per leg at a controlled pace), followed by ingestion of a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate mixed with 200 mL water.

  • PlaceboOther

    Microcrystalline cellulose was administered orally in an opaque capsule at 18:00. Placebo capsules were matched to caffeine capsules for appearance, mass, colour, and odour.

Study groups in NCT07652424
Study groupRoleWhat they receive
PLAPlacebo comparatorPlacebo capsule (microcrystalline cellulose) at 18:00, no nap opportunity
Receives: Other: Placebo
NAPExperimental90-minute afternoon nap opportunity (13:00-14:30) with objective sleep architecture recording via portable EEG headband (Dreem 3), followed by placebo capsule (microcrystalline cellulose) at 18:00. Participants remained in a quiet, dimly lit room during the nap opportunity.
Receives: Behavioral: Afternoon Nap; Other: Placebo
CAFExperimentalCaffeine ingestion (5 mg/kg body mass of anhydrous caffeine) at 18:00, no nap opportunity. Participants remained in a quiet, dimly lit room during the 13:00-14:30 period.
Receives: Dietary Supplement: Caffeine
NAP+CAFExperimental90-minute afternoon nap opportunity (13:00-14:30) with EEG recording, followed by caffeine ingestion (5 mg/kg) at 18:00.
Receives: Behavioral: Afternoon Nap; Dietary Supplement: Caffeine
NAP+CAF+RECExperimental90-min afternoon nap opportunity (13:00-14:30) with portable EEG monitoring, caffeine ingestion (5 mg/kg body mass) at 18:00, and a 15-min standardised active recovery and nutritional protocol from 18:45 to 19:00. The protocol included lower-limb dynamic stretching followed by a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate.
Receives: Behavioral: Afternoon Nap; Dietary Supplement: Caffeine; Combination Product: Standardised Active Recovery and Nutritional Protocol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Repeated Modified Agility Test (RMAT) Total Time

    Total time (seconds) to complete 10 maximal 20-m sprints with four changes of direction (forward sprint, left shuffle, right shuffle, backward sprint). The test was conducted on an indoor hardwood court using dual-beam photocells (Brower Timing Systems, Salt Lake City, UT, USA) placed at the start/finish line. Participants started from a standing position 0.5 m behind the first photocell. Lower values indicate better repeated agility performance. This was the primary outcome measure used for sample size calculation.

    Measured: At approximately 19:35 on each of the five experimental days

Secondary outcomes (10)
  1. Countermovement Jump (CMJ) Height

    Maximum jump height (cm) calculated from flight time using the formula h = g·t²/8, where g = 9.81 m·s-². Participants started from an upright standing position, performed a rapid downward movement to approximately 90° knee flexion, and immediately jumped vertically, maintaining hands on hips throughout. Three maximal attempts were performed with 2 minutes of rest between attempts; the highest jump height was retained. Measured using an optical measurement system (Optojump Next, Microgate SRL, Bolzano, Italy) with a sampling frequency of 1000 Hz. Higher values indicate better explosive lower-limb performance.

    Measured: At approximately 19:20 on each of the five experimental days.

  2. Squat Jump (SJ) Height

    Maximum jump height (cm) from a static squat position with knees at approximately 90° flexion, hands on hips. Participants held the starting position for 2-3 seconds before jumping vertically without any countermovement. Three maximal attempts were performed with 2 minutes of rest between attempts; the highest jump height was retained for analysis. Calculated from flight time using h = g·t²/8. Measured using Optojump Next optical system (1000 Hz sampling frequency). Higher values indicate better explosive lower-limb performance without stretch-shortening cycle contribution.

    Measured: At approximately 19:25 on each of the five experimental days.

  3. 20-m Sprint Time

    Best time (seconds) of two maximal 20-m sprints from a standing start, with 3 minutes of passive recovery between sprints. Participants started 0.5 m behind the start line. Sprint time was measured using dual-beam photocells (Brower Timing Systems, Salt Lake City, UT, USA) placed at the start (0 m) and finish (20 m) lines. Lower values indicate better linear sprint performance.

    Measured: At approximately 19:45 on each of the five experimental days.

  4. Simple Reaction Time (SRT)

    Mean reaction time (milliseconds) across 15 recorded trials. A green circle appeared on a black background on a 15-inch laptop screen (60 Hz refresh rate), and participants pressed the space bar as quickly as possible. Inter-trial interval varied randomly between 1000 and 2000 ms. Measured using OpenSesame software (version 3.3). Lower values indicate faster simple reaction time and better cognitive processing speed.

    Measured: At approximately 19:15 on each of the five experimental days.

  5. Choice Reaction Time (CRT)

    Mean reaction time (milliseconds) across 15 recorded trials. Either a red circle (press the left arrow key) or a blue square (press the right arrow key) appeared randomly on a 15-inch laptop screen (60 Hz refresh rate). Participants had to identify the stimulus and press the correct key as quickly as possible. Inter-trial interval varied randomly between 1000 and 2000 ms. Measured using OpenSesame software (version 3.3). Lower values indicate faster choice reaction time and better cognitive decision-making speed.

    Measured: At approximately 19:20 on each of the five experimental days.

  6. Heart Rate Variability (RMSSD and HF Power)

    Heart-rate variability was recorded during 5-min supine resting measurements with spontaneous breathing using a Polar H10 chest strap. RR intervals were analysed using Kubios HRV software after artefact correction. The main HRV variables were RMSSD (ms) and high-frequency power (0.15-0.40 Hz, normalised units).

    Measured: At 12:00, 18:00, and approximately 19:45 on each of the five experimental days.

  7. Salivary Cortisol Concentration

    Salivary cortisol concentration (nmol/L) measured using Salivette cotton swabs (Sarstedt, Nümbrecht, Germany). Participants were instructed to avoid eating, drinking (except water), and brushing teeth for 30 minutes before each sample. Samples were centrifuged at 1500×g for 10 minutes at 4°C, and the supernatant was stored at -80°C until analysis. Cortisol concentration was measured in duplicate using a high-sensitivity enzyme-linked immunosorbent assay (ELISA, IBL International, Hamburg, Germany) with a detection limit of 0.05 ng/mL and intra- and inter-assay coefficients of variation < 8%. Lower values indicate reduced hypothalamic-pituitary-adrenal (HPA) axis activity.

    Measured: At 12:00, 18:00, approximately 19:45, and 30 minutes after exercise on each of the five experimental days.

  8. Plasma Brain-Derived Neurotrophic Factor (BDNF)

    BDNF concentration (pg/mL) measured in venous blood samples (5 mL) drawn from an antecubital vein. Blood was collected into EDTA tubes, immediately centrifuged at 1500×g for 15 minutes at 4°C, and plasma was stored at -80°C until analysis. BDNF concentration was quantified using a commercially available ELISA kit (R\&D Systems, Minneapolis, MN, USA; catalogue number DBD00) with a detection limit of 20 pg/mL and intra- and inter-assay CVs < 6% and < 9%, respectively. Higher values indicate greater neurotrophic activity.

    Measured: Measured at baseline and after completion of the evening testing battery on each experimental day.

  9. Blood Lactate Concentration

    Lactate concentration (mmol/L) measured in capillary blood samples (5 µL) collected from the fingertip using a Lactate Pro 2 analyzer (Arkray, Kyoto, Japan), which has a coefficient of variation < 3%. Higher values indicate greater metabolic perturbation and glycolytic activation during high-intensity exercise.

    Measured: At 18:55, 3 minutes after the Repeated Modified Agility Test, and 3 minutes after the 20-m sprint on each of the five experimental days.

  10. Nap Architecture (EEG)

    Objective sleep parameters recorded using a validated dry-electrode portable EEG headband (Dreem 3, Paris, France) with six channels (F3, F4, C3, C4, O1, O2, referenced to linked mastoids). Sleep stages were automatically scored in 30-second epochs using the manufacturer's algorithm and visually corrected by a certified sleep technologist blinded to condition and participant. Parameters extracted: total sleep time (TST, minutes), sleep onset latency (SOL, minutes), time in N2 sleep (minutes), time in N3 slow-wave sleep (minutes), time in REM sleep (minutes), and sleep efficiency (TST/time in bed × 100, %).

    Measured: During the 90-minute nap opportunity from 13:00 to 14:30 on NAP, NAP+CAF, and NAP+CAF+REC condition days only.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jun 2026
  2. Study start2 Jan 2025
  3. Primary completion31 May 2025
  4. Study completion31 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Model description
Randomised, counterbalanced crossover design with 5 experimental conditions. Each participant completes all conditions in a different order determined by Latin square randomisation. Washout period between conditions: at least 72 hours.
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07652424
Sponsor's protocol ID
ISSEPS-NAP-CAF-REC-2025
Acronym
NAP-CAF-REC
Status last verified
Jun 2026
First submitted
10 Jun 2026
Last updated
30 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Anonymised individual participant data (IPD) will be shared for all 60 participants across all five experimental conditions (300 experimental sessions). Data will include: demographic characteristics, anthropometric measures, chronotype classification (MEQ scores), sleep quality (PSQI scores), nap architecture (EEG-derived sleep stages), physical performance outcomes (RMAT, CMJ, SJ, 20-m sprint), cognitive performance outcomes (SRT, CRT), subjective sleepiness (ESS, KSS), and physiological biomarkers (HRV-RMSSD, HF power, salivary cortisol, plasma BDNF, blood lactate). All data will be fully anonymised using coded identifiers (S01-S60), with the identification key stored separately on encrypted institutional servers.

Questions about this trial

What is this clinical trial studying?

A study testing Afternoon Nap, Caffeine and Standardised Active Recovery and Nutritional Protocol in people with Athletic Performance and Sports Performance, run by The Higher Institute of Sport and Physical Education of Sfax at 1 site in Tunisia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Repeated Modified Agility Test (RMAT) Total Time (time frame: At approximately 19:35 on each of the five experimental days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in